The Bioprocessing Research Industry Club (BRIC), a public-private collaboration between two Research Councils and the UK biopharmaceutical community, has awarded £3.5 million to researchers at seven universities. The funding will bring new treatments a step closer by helping to develop faster and more efficient development and manufacturing techniques.
Biopharmaceuticals account for 30 per cent of drugs currently in development, and 10 per cent of the current market. Examples of current biopharmaceutical treatments include the use of therapeutic proteins to manage conditions associated with hormone deficiencies or cancers of breast, colon, prostate or pancreatic tissues. In the future, biopharmaceutical treatments may also be able to help with organ and tissue deficiencies or disease conditions associated with ageing. The projects funded by BRIC aim to improve the bioprocessing techniques and systems that underpin biopharmaceutical development and production.
This is the second round of funding awarded by BRIC - a funding collaboration between the Biotechnology and Biological Sciences Research Council (BBSRC), the Engineering and Physical Sciences Research Council (EPSRC) and the UK biopharmaceutical industry, with support from bioProcessUK. It has awarded funding to eight research teams at seven universities: the Universities of Birmingham, Imperial College London, Manchester, Newcastle, Nottingham, Sheffield and Strathclyde.
These projects build on the first round of BRIC funding which supported nine projects at ten universities with funds in excess of £5 million. The third and final call for BRIC will be announced in the next few weeks.
By combining funding from major public funders and industry, BRIC works to support the rapidly growing biological medicines industry in the UK, with the ultimate aim of accelerating therapy development for patients.
Dr John Birch, Chairman of the BRIC steering group and Chief Scientific Officer at Lonza Biologics, said: "Biological drug development offers tremendous promise for patients. The eight new projects funded by BRIC will make a significant contribution to the research underpinning bioprocessing and will help to provide both faster process development and more efficient manufacturing technology for new biopharmaceuticals."
Dr Doug Yarrow, BBSRC Director of Corporate Science said: "The UK has an outstanding research base in bioprocessing and the latest round of BRIC grants further promotes the UK's world-leading status. It is essential that research capabilities are translated into real benefits for patients. BRIC's funding enables this by strengthening the vital links between groundbreaking research in our universities and industry's needs."
Michelle Kilfoyle | alfa
Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover
First transcription atlas of all wheat genes expands prospects for research and cultivation
17.08.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Physics and Astronomy
17.08.2018 | Information Technology
17.08.2018 | Life Sciences